Site A: Raw Materials
Minhang, Shanghai
· Phosphoramidites: 8 tons
· NTP: 18,000 liters
With nearly 30 years of RNA-focused expertise, Hongene offers seamless support from raw materials to GMP drug products. Our vertically integrated platform simplifies complex supply chains, reduces risk, and speeds your program to market—all while ensuring quality you can trust.
From raw materials to GMP drug product: Fewer handoffs, faster timelines, greater confidence.
End-to-end CDMO services for oligonucleotide therapeutics, from early development through cGMP clinical supply and commercial manufacturing.
End-to-end CDMO services for mRNA therapeutics, from IVT template preparation through formulation and fill-finish.
Custom synthesis of nucleic acid building blocks, monomers, and specialty reagents
Explore raw material categories for RNA therapeutics, from synthesis building blocks to enzymes and cap analogs.
Material spotlight
Phosphoramidites
Unmatched purity, multi-ton capacity, and a comprehensive portfolio.
Material spotlight
Nucleosides
Natural and modified nucleosides manufactured in-house, guaranteed high quality starting at the source.
Material spotlight
Nucleoside Triphosphate
Enzymatic-grade purity, a broad modified portfolio, and GMP supply built for scale.
Material spotlight
Enzyme
High specific activity, ultra-low impurities, and GMP-grade lot-to-lot consistency.
Material spotlight
Cap Analog
Rationally designed and optimized for robust protein expression
Material spotlight
GalNAc
Enable precise liver targeting, efficient cellular uptake, and improved pharmacokinetics.
Powering RNA programs with deep expertise, consistent high quality, and capacity built for scale.
28 Years
RNA-focused expertise
~2,000
Global Workforce
~400 FTEs in R&D
2,000+
product SKUs
2,000+
impurity profiles
Multi-Ton
oligo DS capacity
58 tons
annual phosphoramidite capacity
Integrated supply and specialized technologies to support the development and manufacture of RNA therapeutics.
From building blocks to drug substance and drug product, Hongene’s vertically integrated platform reduces handoffs, improves continuity and supports more efficient program execution.
Chemoenzymatic LigationSupport next-generation oligonucleotide therapeutics by improving scalability and manufacturing efficiency for selected applications, including siRNA, dual-target siRNA, ADC, sgRNA, and pegRNA.
mRNA Cap TechnologyA new generation of rationally designed 5’ cap structures to enhance mRNA translation efficiency by reducing IFIT1-mediated immune suppression.
Manufacturing sites in Shanghai and a phased build-out in Hungary support raw materials, oligonucleotide CDMO and mRNA CDMO capabilities.
The latest articles on Hongene's technology sharing and industry insights.
Demand for nucleic acid therapeutics (NATs) is expanding as mRNA and oligonucleotide therapeutics advance beyond rare diseases into high-prevalence indications, particularly cardiometabolic conditions such as hypertension and dyslipidemia. For example,...